ADVANCING NOVEL GPCR-TARGETED CANDIDATES
We are currently advancing multiple small molecule candidates through lead optimization and pre-clinical development against GPCR targets involved in respiratory, CNS, metabolic, and other diseases. We are also helping advance candidates in collaboration with biopharmaceutical partners.
| Program Indication | Structure Elucidation | Lead Generation | Lead Optimization | IND Enabling Studies | Early Clinical |
|---|---|---|---|---|---|
|
Partner Program - Target A
Metabolic
|
X
|
||||
|
Partner Program - Target B
Metabolic
|
X
|
||||
|
D1 dopamine
Parkinson's Disease
|
X
|
||||
|
D2 dopamine
Psychiatric Disorders
|
X
|
||||
|
GPR75
Metabolic
|
X
|
||||
|
GPR171
Pain
|
X
|
||||
